Meet the Veracyte® Breast Cancer team at the 8th World Congress on Controversies in Breast Cancer (CoBrCa) at Booth #12!

Breakfast Symposium supported by Veracyte:
“What is the true utility of Genomic Testing in Early Breast Cancer? A closer look at intrinsic subtyping and Prosigna.”

Thursday, September 12
07:30 am – 08:30 am
Hall A

Chair: Prof Dame Lesley Fallowfield

Speakers:

• Professor Matt Ellis – The clinical utility of PAM50 and intrinsic subtyping and a comparison of the available technologies

• Professor Stuart McIntosh – Prognostication vs Prediction. A review of the available evidence and a discussion around the value of the OPTIMA study

• Professor Dame Lesley Fallowfield – How well do healthcare professionals and patients understand the information provided by genomic test reports?

Learn more about the Prosigna® Breast Cancer Assay, the breast cancer risk of recurrence test that confidently guides treatment decisions.